发明名称 |
Compounds, compositions and methods for making the same |
摘要 |
The present invention provides compounds and/or compositions that modulate PP2A methylation and/or activity and methods for preparing the same, which are useful for modulating the demethylation of PP2A, modulating the methylation of PP2A and/or modulating the activity of PP2A. |
申请公布号 |
US9486441(B2) |
申请公布日期 |
2016.11.08 |
申请号 |
US200912427743 |
申请日期 |
2009.04.21 |
申请人 |
SIGNUM BIOSCIENCES, INC. |
发明人 |
Vafai Scott;Voronkov Michael;Stock Maxwell;Stock Jeffry B.;Lee Seung-Yub;Li Zhu;Gu Haoming |
分类号 |
A61K31/405 |
主分类号 |
A61K31/405 |
代理机构 |
McCarter & English, LLP |
代理人 |
McCarter & English, LLP ;Tu Peter |
主权项 |
1. A method for reducing the severity of symptoms in a subject suffering from a neurodegenerative disease or disorder, the method comprising administering to the subject a therapeutic amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises at least 8.0 mg of a composition consisting essentially of an at least 80% or above pure or synthetic compound selected from the group consisting of: or a mixture of compounds I-62 and I-63, wherein the pharmaceutical composition is further characterized by: the therapeutic amount being effective to modulate phosphatase activity of protein phosphatase 2A (PP2A) in nerve cells, containing less than 10% of caffeine, caffeic acid, and chlorogenic acid; and the neurodegenerative disease is characterized by: (1) abnormal methylation of protein phosphatase 2A (PP2A) and hyperphosphorylation of tau; or (2) abnormal methylation of protein phosphatase 2A (PP2A) and abnormal phosphorylation of alpha-synuclein; or (3) abnormal protein phosphatase 2A (PP2A) activity; hyperphosphorylation of tau, and abnormal phosphorylation of alpha-synuclein; or a combination thereof; wherein I-62 and I-63 are the only compounds in the composition that modulate PP2A activity in nerve cells. |
地址 |
Princeton NJ US |